慢性乙型肝炎相关肝硬化患者治疗后肝脏纤维化程度改变研究进展  

Research advance of the liver fibrosis degree change in patients with HBV-related cirrhosis after long-term antiviral treatment

作　　者：吴青青 尹乔乔 郑伟[3] 鲍素霞 潘红英[3] Wu Qingqing;Yin Qiaoqiao;Zheng Wei;Bao Suxia;Pan Hongying(The Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,China;Graduate College of Bengbu Medical College,Bengbu 233030,Anhui,China;Department of Infectious Diseases,Zhejiang Provincial People's Hospital,Hangzhou 310014,China)

机构地区：[1]浙江中医药大学第二临床医学院,杭州310053 [2]蚌埠医学院研究生院,安徽蚌埠233030 [3]浙江省人民医院感染病科,杭州310014

出　　处：《国际流行病学传染病学杂志》2019年第3期251-253,共3页International Journal of Epidemiology and Infectious Disease

摘　　要：肝硬化常被认为是肝脏疾病发展的终末阶段,但有效的针对性治疗可以改变其病理状态,甚至逆转。我国肝硬化最常见的病因是肝炎病毒感染,本综述重点阐述由HBV感染进展的肝硬化患者应用恩替卡韦、替诺福韦酯等抗病毒药物长期治疗后,肝脏纤维化程度的改变情况。Liver cirrhosis is often considered as the final stage in the development of liver diseases. However, effective etiological treatment can change its pathological state and even reverse. The most common cause of liver cirrhosis in China is the infection of hepatitis virus. The review focuses on changes of liver fibrosis degree in patients with HBV-related cirrhosis after long-term antiviral agents, such as entecavir and tenofovir.

关 键 词：肝硬化 抗病毒治疗 逆转 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]